Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $317,135 | 129 | 82.4% |
| Consulting Fee | $43,938 | 18 | 11.4% |
| Travel and Lodging | $14,276 | 78 | 3.7% |
| Food and Beverage | $9,446 | 134 | 2.5% |
| Education | $259.05 | 6 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $153,631 | 151 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $65,777 | 33 | $0 (2024) |
| PFIZER INC. | $40,108 | 27 | $0 (2023) |
| Janssen Biotech, Inc. | $37,561 | 48 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $33,083 | 35 | $0 (2024) |
| Lilly USA, LLC | $20,064 | 28 | $0 (2024) |
| Daiichi Sankyo Inc. | $14,124 | 12 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $9,202 | 6 | $0 (2022) |
| Celltrion USA Inc. | $5,478 | 8 | $0 (2024) |
| Janssen Global Services, LLC | $4,200 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61,692 | 53 | Janssen Biotech, Inc. ($23,932) |
| 2023 | $51,503 | 49 | ABBVIE INC. ($17,351) |
| 2022 | $41,501 | 33 | Janssen Scientific Affairs, LLC ($13,701) |
| 2021 | $59,794 | 37 | E.R. Squibb & Sons, L.L.C. ($30,928) |
| 2020 | $28,585 | 33 | AbbVie Inc. ($19,905) |
| 2019 | $44,194 | 40 | AbbVie, Inc. ($25,908) |
| 2018 | $61,860 | 63 | AbbVie, Inc. ($49,161) |
| 2017 | $35,925 | 57 | AbbVie, Inc. ($15,497) |
All Payment Transactions
365 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $554.00 | General |
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $7,199.00 | General |
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $277.50 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $122.92 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,110.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Immunology | ||||||
| 10/28/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,104.50 | General |
| Category: Neuroscience | ||||||
| 10/21/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Travel and Lodging | Cash or cash equivalent | $53.00 | General |
| Category: Immunology | ||||||
| 10/21/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Food and Beverage | Cash or cash equivalent | $16.49 | General |
| Category: Immunology | ||||||
| 10/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 10/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 10/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | Cash or cash equivalent | $63.65 | General |
| Category: Immunology | ||||||
| 10/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | Cash or cash equivalent | $55.05 | General |
| Category: Immunology | ||||||
| 10/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: Immunology | ||||||
| 10/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 10/10/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,110.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/08/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 09/28/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Food and Beverage | In-kind items and services | $59.33 | General |
| Category: Immunology | ||||||
| 09/28/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Food and Beverage | In-kind items and services | $38.93 | General |
| Category: Immunology | ||||||
| 09/28/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Food and Beverage | In-kind items and services | $38.15 | General |
| Category: Immunology | ||||||
| 09/27/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Travel and Lodging | In-kind items and services | $318.31 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 241 | 261 | $172,028 | $36,243 |
| 2022 | 9 | 295 | 313 | $198,155 | $46,760 |
| 2021 | 8 | 277 | 290 | $177,918 | $41,841 |
| 2020 | 9 | 211 | 224 | $113,151 | $27,604 |
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 78 | 97 | $38,068 | $13,871 | 36.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 48 | 48 | $52,272 | $6,483 | 12.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 21 | 21 | $16,191 | $4,013 | 24.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 24 | $11,664 | $3,556 | 30.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $7,785 | $2,582 | 33.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 30 | 30 | $30,956 | $2,344 | 7.6% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $10,032 | $1,795 | 17.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $5,060 | $1,599 | 31.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 75 | 89 | $31,417 | $13,068 | 41.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 60 | 62 | $67,518 | $8,253 | 12.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 36 | $17,489 | $6,241 | 35.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 29 | 29 | $14,587 | $5,381 | 36.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 21 | 21 | $15,855 | $4,842 | 30.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 34 | 35 | $35,315 | $2,985 | 8.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 12 | 12 | $5,964 | $2,550 | 42.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 18 | 18 | $7,260 | $2,433 | 33.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 11 | $2,750 | $1,007 | 36.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 74 | 86 | $30,358 | $13,583 | 44.7% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 59 | 59 | $64,251 | $7,692 | 12.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 36 | 36 | $17,489 | $6,278 | 35.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 31 | 31 | $12,431 | $4,415 | 35.5% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 13 | 13 | $9,815 | $2,898 | 29.5% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 31 | 31 | $31,279 | $2,599 | 8.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 15 | 15 | $7,545 | $2,593 | 34.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 19 | $4,750 | $1,783 | 37.5% |
About Dr. Mark Mattar, MD
Dr. Mark Mattar, MD is a Gastroenterology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1841401031.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Mattar, MD has received a total of $385,054 in payments from pharmaceutical and medical device companies, with $61,692 received in 2024. These payments were reported across 365 transactions from 16 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($317,135).
As a Medicare-enrolled provider, Mattar has provided services to 1,024 Medicare beneficiaries, totaling 1,088 services with total Medicare billing of $152,448. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology, Gastroenterology
- Location Washington, DC
- Active Since 05/27/2007
- Last Updated 01/17/2019
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1841401031
Products in Payments
- Humira (Biological) $60,817
- ZEPOSIA (Drug) $58,093
- STELARA (Biological) $53,909
- XELJANZ (Drug) $40,040
- HUMIRA (Biological) $29,553
- SKYRIZI (Biological) $16,834
- RINVOQ (Biological) $16,679
- TREMFYA (Drug) $16,636
- INJECTAFER (Drug) $14,124
- OMVOH (Drug) $11,092
- ENTYVIO (Biological) $9,202
- ZYMFENTRA (Biological) $5,478
- REMICADE (Biological) $99.00
- Vemlidy (Drug) $96.83
- VOWST (Biological) $47.25
- Cimzia (Drug) $43.10
- GED-0301 (Drug) $17.00
- GENERAL POLYPECTOMY (Device) $14.86
- EXALT Model D (Device) $13.17
- Ozanimod (Drug) $12.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Washington
James Lewis
Gastroenterology — Payments: $1.2M
Dr. John Hogan, M.d, M.D
Gastroenterology — Payments: $533,987
Jessica Korman, M.d, M.D
Gastroenterology — Payments: $114,919
Dr. Roshan Bashir, M.d, M.D
Gastroenterology — Payments: $61,004
Dr. Dominique Howard, M.d, M.D
Gastroenterology — Payments: $27,909
Lauren George, M.d, M.D
Gastroenterology — Payments: $24,323